Compare Adaptive Biotechnologies Corp (ADPT) vs Zscaler Inc (ZS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Zscaler Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.13 (market cap $3.33B), while Zscaler Inc trades at $143.31 (market cap $24.18B). The key difference: Zscaler Inc is far larger — about 7.3× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | ZS | |
|---|---|---|
Market Cap | $3.33B | $24.18B |
Sector | Health | Technology |
52-Week High | $22.37 | $336.27 |
52-Week Low | $10.24 | $118.05 |
Enterprise Value | $3.19B | $22.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Zscaler (ZS) trades at $149.50, up 1.47% with strong technical momentum and bullish moving average signals. The company shows impressive revenue growth from $1.1B in 2022 to $2.67B in 2025, though remains unprofitable with a -2.44% net margin. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.08 surpassing the $1.01 forecast. Technical indicators show the stock trading near pivot point resistance at $149 with support at $145.
ZS presents a growth investment case with 79% analyst buy ratings and $192.64 consensus target, offering 29% upside. However, profitability challenges, ongoing class action investigations, and projected negative 2026 cash flow pose significant risks. The stock's high valuation multiples (P/S 7.53, EV/EBITDA 157.24) require sustained growth execution to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
